Truist Financial analyst Joon Lee maintains $Editas Medicine (EDIT.US)$ with a buy rating.
According to TipRanks data, the analyst has a success rate of 54.5% and a total average return of 29.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Editas Medicine (EDIT.US)$'s main analysts recently are as follows:
The firm believes that Editas Medicine's shift towards an in vivo SCD approach and the decision to partner out reni-cel may be a more strategic allocation of its expertise and resources, potentially leading to greater value creation, following the successful preclinical in vivo editing of HSPCs.
Editas Medicine has presented initial data from its in vivo approach, which involves the targeted lipid nanoparticle delivery to edit hematopoietic stem cells with the CRISPR-Cas12a enzyme. Alongside this, the company has expressed its intention to form global partnerships for reni-cel, prioritizing its resources on in vivo programs. Despite the promising early in vivo data, there is an expectation that investors may find it challenging to place significant value on a platform at such an initial stage of development.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
